AOD-9604: animal studies vs human evidence, explained

Last updated 2026-07-25

What is AOD-9604 and why did animal data get everyone excited?

AOD-9604 is a synthetic fragment of human growth hormone, built from amino acids 176-191, the tail end of the hGH molecule. Researchers isolated that region because it seemed to carry the fat-metabolizing (lipolytic) signal of growth hormone without the growth-promoting, insulin-resistance-inducing effects that come with the rest of the molecule. The idea had a clean mechanistic logic to it: keep the part of hGH that tells fat cells to release stored fat and burn it, drop the part that grows bone and cartilage and messes with blood sugar. That's a genuinely elegant hypothesis, and it's why AOD-9604 got taken seriously enough to reach human trials at all, unlike a lot of peptides that never leave the lab. A 2004 review in Current Opinion in Investigational Drugs describes AOD-9604's proposed metabolic action, framing it specifically around this fat-fragment mechanism ^[1]. That's the whole animal-and-mechanism case in one sentence: a hormone fragment engineered to isolate a metabolic effect. It's a real, testable hypothesis. It is not the same thing as proof that it works in a person trying to lose 15 pounds. What animal studies can't tell you is whether the effect is big enough, in a real human body, on a real dosing schedule, to matter. That's what the human trials were supposed to settle. If you want the deeper mechanism writeup, we cover the fragment rationale in more detail on the AOD-9604 peptide hub page.

Did AOD-9604 actually work in human obesity trials?

This is the part that matters most, so let's be direct about it: AOD-9604 went through human obesity trials, and the weight-loss results did not separate convincingly from placebo. The drug's development history is documented in a set of "Gateways to clinical trials" reports published in Methods and Findings in Experimental and Clinical Pharmacology, which tracked AOD-9604 as it moved through Phase II development around 2003 to 2005 ^[2][3][4]. These gateway reports are essentially clinical-trial-pipeline roundups, not full efficacy papers, but they're the paper trail that confirms AOD-9604 reached human obesity testing under Metabolic Pharmaceuticals (the Australian company that developed it) and that it did not deliver a clean, replicated win. A separate 2006 review of obesity drugs in clinical development situates AOD-9604 among the crowded field of anti-obesity compounds being tested in the mid-2000s, most of which also failed to reach approval ^[5]. That review is useful context: AOD-9604 wasn't unique in stalling out. Most obesity candidates from that era did. No AOD-9604 product has ever reached FDA approval for weight loss or any other indication. You can confirm this yourself by searching Drugs@FDA, the FDA's own database of approved drug products; AOD-9604 does not appear there ^[6]. That's the single cleanest fact in this whole story: after roughly two decades of on-and-off development, there is still no approved AOD-9604 drug on the market anywhere in a major regulated jurisdiction. If a compound had a strong, replicated fat-loss signal in Phase II humans, it doesn't just quietly disappear from a pharma company's pipeline. It gets pushed hard into Phase III. AOD-9604 didn't get pushed. That absence is itself data.

Why didn't the human trial results match the animal and cell-based promise?

The honest answer is nobody has published a definitive mechanistic explanation, but a few things line up. First, effect sizes in rodent lipolysis assays and isolated fat-cell studies often don't scale linearly to whole-body human metabolism, especially for a peptide with a short half-life given by injection at doses far below what produces measurable lipolysis in a dish. Second, human obesity is metabolically messier than a controlled animal model: appetite, activity level, insulin sensitivity, and sleep all interact in ways a rodent study or in vitro assay doesn't capture. Third, and this is the more mundane explanation: a lot of promising fragment and analog peptides simply don't clear the bar in Phase II once you control for placebo response, dropout, and measurement noise. The 2006 clinical-development review lists several anti-obesity peptides and small molecules from the same era that had reasonable preclinical stories and then failed to show a clear, dose-dependent human signal ^[5]. AOD-9604 fits that pattern rather than breaking it. This is why the animal-to-human gap matters so much for anyone evaluating a peptide's claims. A compound can have a completely real, reproducible effect in a rat and still not move the needle in a human obesity trial. That's not fraud or bad science. It's just how much drug development attrition happens between mechanism and outcome, and AOD-9604 is a textbook case of it.

Is AOD-9604 still being studied for anything today?

Yes, but the current research focus has shifted almost entirely away from fat loss and toward orthopaedic and musculoskeletal applications. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews covers therapeutic peptides in orthopaedics, including AOD-9604's proposed cartilage-related applications, as part of a broader survey of peptide therapeutics entering that field ^[7]. A companion 2026 review in Sports Medicine specifically evaluates the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, again placing AOD-9604 in that category rather than the metabolic/weight-loss category ^[8]. That's a real pivot worth noting. The fat-loss story is old (2000s-era Metabolic Pharmaceuticals trials); the newer research interest is in cartilage and joint applications, which is a genuinely different question with its own separate, still-thin evidence base. If you're reading marketing copy that cites "new studies" on AOD-9604, ask which category those studies fall into. Cartilage research says nothing about fat loss, and vice versa. Neither of these 2026 reviews claims AOD-9604 is an approved orthopaedic therapy. They're describing an area of interest, not a finished product.

Does AOD-9604 show up on a drug test or WADA screen?

There's decent analytical chemistry research on this specific question, separate from the efficacy question entirely. A 2013 study in Drug Testing and Analysis tested whether AOD-9604 interferes with the World Anti-Doping Agency's hGH isoform immunoassay, the test used to catch growth hormone doping in athletes. The study concluded AOD-9604 does not influence the WADA hGH isoform immunoassay ^[9], meaning it won't cause a false positive or false negative on that specific screening test the way some had speculated a growth hormone fragment might. That doesn't mean AOD-9604 is untestable or ignored by anti-doping labs. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on detecting emerging therapeutics and non-approved drugs in doping controls covers AOD-9604 among the peptide compounds analytical chemists have developed detection methods for ^[10]. A separate 2014 review in Expert Review of Proteomics on detecting peptidic drugs and analogs in sports doping likewise treats AOD-9604 as one of the smaller peptide fragments requiring specific mass-spectrometry-based detection approaches, distinct from the standard hGH isoform test ^[11]. A 2016 method paper in the Journal of Separation Science describes techniques for screening peptides under 2 kDa (AOD-9604 is roughly 1.8 kDa) by direct urine injection combined with liquid chromatography and ion mobility mass spectrometry, again as part of building out detection coverage for small peptide fragments ^[12]. The practical takeaway: AOD-9604 sits in a gray zone on standard hGH tests but is very much on the radar of dedicated anti-doping mass spectrometry panels. If you're a tested athlete, don't assume it's invisible.

Is AOD-9604 legal, and how is it actually sold?

AOD-9604 is not an FDA-approved drug for any use, and it does not appear on either FDA bulk drug substance list that governs what compounding pharmacies can legally use. Under federal law, compounding pharmacies operate through two main pathways: 503A pharmacies (traditional compounding, patient-specific prescriptions) and 503B outsourcing facilities (larger-scale compounding without a patient-specific prescription requirement). Both pathways are limited to substances on their respective FDA bulk drug substance lists, found at 21 CFR 216.23 for 503A and 21 CFR 216.24 for 503B ^[13][14], or substances that otherwise meet the compounding criteria under 21 U.S.C. 353a ^[15]. AOD-9604 is not on either current list; you can check FDA's own bulk substances page and the nominated-substances list to confirm ^[16][17]. That's why legitimate AOD-9604 in the US is sold almost exclusively labeled "research use only," not as a prescription product for human use. Under 21 CFR 201.128, a product's "intended use" is determined by labeling, advertising, and how it's marketed, more than what's printed on the vial ^[18]. Selling a research-labeled peptide while marketing it for personal fat loss creates a real regulatory mismatch, and it's part of why sourcing quality and provider practices vary so much across the market. If you're going to look at this compound at all, the sourcing question deserves its own real scrutiny. We've written a longer guide on where to buy AOD-9604 and a separate rundown of AOD-9604 for sale listings, covering what separates a provider that does third-party testing from one that doesn't.

How does AOD-9604's evidence compare to other fat-loss and GH-related peptides?

This is the comparison that actually matters if you're deciding what to spend money on.

Tesamorelin is the most useful comparison because it's also a growth-hormone-axis peptide, just a releasing hormone rather than a fragment, and it actually has FDA approval and a real efficacy record, though for a narrower indication (HIV lipodystrophy, not general obesity). We break that comparison down in full on AOD-9604 vs tesamorelin. GLP-1 drugs aren't peptide-fragment cousins of AOD-9604 mechanistically, but they're the honest benchmark for "does this actually produce weight loss in humans," and the gap between their trial results and AOD-9604's is not close. If your only goal is fat loss and you want a compound with a real human efficacy record behind it, AOD-9604 is not where that evidence currently points.

What does the animal-vs-human gap mean for someone considering AOD-9604 today?

It means treat the fat-loss claim as unproven, not as debunked nonsense and not as settled science either. It sits in an honest middle: real mechanistic rationale, real animal and cell data, and a human trial record that didn't confirm the story. If you're set on trying it anyway, go in with calibrated expectations. Don't expect GLP-1-level or even tesamorelin-level results. Track your own numbers (weight, waist circumference, maybe a DEXA scan if you can get one) rather than relying on subjective "I feel leaner" impressions, because placebo response in body composition self-assessment is well documented and exactly the effect the human trials were designed to control for. Sourcing matters more than usual here precisely because there's no FDA-approved reference product to compare against. A provider-reviewed source that does third-party purity and identity testing is the baseline, not a bonus. AOD-9604 Co reviews providers against that standard and points toward pharmacy partners that fulfill orders with documented testing, rather than unverified drop-shippers. If you're past the "should I" question and into logistics, our guides on when to take AOD-9604 and how to reconstitute AOD-9604 cover the practical dosing mechanics people ask about most.

What would it take for AOD-9604's human evidence to actually improve?

A properly powered, modern Phase II or III trial with objective body composition endpoints (DEXA-measured fat mass, more than scale weight) and a large enough sample to detect a modest effect size, if one exists. That hasn't happened. The last substantive human obesity trial activity traceable in the literature is the mid-2000s Metabolic Pharmaceuticals program documented in the Gateways to clinical trials reports ^[2][3][4]. Since then, research interest in AOD-9604 has moved toward orthopaedic and cartilage applications ^[7][8], not toward re-testing the fat-loss claim with better methodology. That's worth sitting with. Nearly two decades is a long time for a compound with a genuinely promising early signal to sit untested for its original indication. In drug development, that usually means either the funding dried up because the signal wasn't strong enough to justify Phase III costs, or someone quietly concluded the effect size in humans is too small to be commercially or clinically meaningful. Either explanation lands in the same place for a consumer: don't expect new fat-loss trial data to show up and vindicate the original claim. The field has moved on to a different question.

Frequently asked questions

Did AOD-9604 pass human clinical trials for weight loss?

No. AOD-9604 reached Phase II human obesity trials under Metabolic Pharmaceuticals in the early-to-mid 2000s, documented in Methods and Findings in Experimental and Clinical Pharmacology's "Gateways to clinical trials" reports, but the weight-loss results did not separate convincingly from placebo, and the drug has never received FDA approval for any use.

What were the original animal studies on AOD-9604 based on?

AOD-9604 is a synthetic fragment of amino acids 176-191 of human growth hormone, isolated because that region appeared to carry hGH's fat-metabolizing (lipolytic) signal without the growth-promoting effects. A 2004 Current Opinion in Investigational Drugs review describes this proposed metabolic mechanism, based on preclinical and cell-based research.

Is AOD-9604 FDA-approved?

No. AOD-9604 does not appear in Drugs@FDA, the FDA's database of approved drug products, and it is not on either the 503A or 503B bulk drug substance lists (21 CFR 216.23 and 216.24) that govern what compounding pharmacies can legally use. It is typically sold labeled for research use only.

Why did AOD-9604 fail to beat placebo in human trials if it worked in animals?

No single published study fully explains the gap, but likely factors include effect sizes from rodent and cell-based assays not scaling to whole-body human metabolism, the added complexity of human appetite and insulin regulation, and the general high attrition rate of anti-obesity compounds in Phase II, a pattern a 2006 obesity drug development review shows AOD-9604 shared with several other candidates from that era.

Is AOD-9604 still being researched today?

Yes, but mostly for orthopaedic and musculoskeletal applications rather than fat loss. Two 2026 reviews, one in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews and one in Sports Medicine, cover AOD-9604 in the context of cartilage and joint-related peptide therapeutics, not as an active weight-loss candidate.

Does AOD-9604 show up on a drug test?

A 2013 Drug Testing and Analysis study found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard growth hormone doping test. However, dedicated mass-spectrometry-based peptide detection methods, described in 2014 and 2016 analytical chemistry papers, can identify AOD-9604 specifically, so it is not undetectable to anti-doping labs overall.

How does AOD-9604 compare to tesamorelin for fat loss?

Tesamorelin is FDA-approved (as Egrifta) specifically for HIV-associated lipodystrophy and has published Phase III trial data showing reductions in visceral adipose tissue. AOD-9604 has no FDA approval and no human trial that beat placebo for fat loss. See our full AOD-9604 vs tesamorelin comparison for the detailed breakdown.

Can I legally buy AOD-9604 in the United States?

AOD-9604 is not on FDA's 503A or 503B bulk drug substance lists, so compounding pharmacies cannot legally sell it as a compounded prescription drug for human use. It is sold as a research-use-only product; marketing it for personal fat loss creates a legal gray area under FDA's intended-use rules at 21 CFR 201.128.

What is the molecular size of AOD-9604 and why does that matter for detection?

AOD-9604 is roughly 1.8 kilodaltons, a small peptide fragment. A 2016 Journal of Separation Science paper specifically describes detection methods for peptides under 2 kDa using direct urine injection with liquid chromatography and ion mobility mass spectrometry, a technique developed partly because small fragments like AOD-9604 are harder to catch with older screening methods.

Has any company continued developing AOD-9604 for obesity since the original trials?

There's no publicly documented Phase III or later-stage obesity trial for AOD-9604 since the mid-2000s Metabolic Pharmaceuticals program. Subsequent published research interest, including two 2026 reviews, has shifted toward orthopaedic and cartilage applications rather than re-testing the original weight-loss claim.

Is the fragment rationale behind AOD-9604 scientifically reasonable?

Yes, as a hypothesis. Isolating the fat-metabolizing region of growth hormone (amino acids 176-191) while dropping growth-promoting regions is a real, testable idea, described in a 2004 Current Opinion in Investigational Drugs review. The problem isn't the logic; it's that the human trials designed to confirm the hypothesis didn't produce a clean result.

Should I expect AOD-9604 to work like a GLP-1 drug for weight loss?

No. GLP-1 agonists like semaglutide and tirzepatide have large Phase III trials showing double-digit percent body weight reduction and FDA approval for weight management. AOD-9604 has no comparable human efficacy data; its Phase II obesity trials did not separate from placebo, so expectations should be set much lower, if you use it at all.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Describes AOD-9604's proposed lipolytic/metabolic mechanism as a growth hormone fragment
2. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Documents AOD-9604's presence in Phase II human obesity clinical trial pipeline reporting
3. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Additional gateway-to-clinical-trials tracking of AOD-9604's Phase II development status
4. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): Later gateway report tracking continued Phase II clinical trial pipeline status for AOD-9604
5. PubMed, Current Opinion in Investigational Drugs (2006): Reviews obesity drugs in clinical development circa 2006, situating AOD-9604 among candidates that largely failed to reach approval
6. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product in this database
7. PubMed, JAAOS Global Research & Reviews (2026): Covers AOD-9604 among therapeutic peptides being explored for orthopaedic applications
8. PubMed, Sports Medicine (2026): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries, including AOD-9604
9. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used in doping tests
10. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Covers analytical detection methods for emerging non-approved therapeutics including AOD-9604 in doping controls
11. PubMed, Expert Review of Proteomics (2014): Reviews detection of peptidic drugs and analogs like AOD-9604 in sports doping using mass spectrometry
12. PubMed, Journal of Separation Science (2016): Describes screening methods for small peptides under 2 kDa, relevant to AOD-9604's roughly 1.8 kDa size
13. eCFR, 21 CFR 216.23: Defines the 503A bulk drug substances list that AOD-9604 does not appear on
14. eCFR, 21 CFR 216.24: Defines the 503B bulk drug substances list that AOD-9604 does not appear on
15. Cornell Law School LII, 21 U.S.C. 353a: Establishes the federal pharmacy compounding framework AOD-9604 falls outside of
16. FDA, Bulk drug substances used in compounding under section 503A: Current FDA reference page confirming which bulk substances compounders may legally use
17. FDA, Bulk drug substances nominated for use in compounding (current list): Lists substances nominated for compounding consideration, used to confirm AOD-9604's absence from approved lists
18. eCFR, 21 CFR 201.128: Defines how a product's marketing and labeling establish its legal intended use